DeepCure Presents Groundbreaking Data on DC-9476
DeepCure is making significant strides in the field of therapeutics, particularly in the treatment of rheumatoid arthritis (RA). At the upcoming ACR Convergence 2024, new in vivo data will be showcased that highlights the efficacy of DC-9476, a selective BRD4 (BD2) inhibitor. This data demonstrates that DC-9476 surpasses traditional treatments such as anti-TNF?, anti-IL6, and the JAK2 inhibitor tofacitinib in a preclinical mouse model for collagen induced arthritis (CIA).
Innovative Findings on DC-9476
Dr. Kulveer Mankia, an esteemed investigator from the Leeds Institute of Rheumatic and Musculoskeletal Medicine, will present ex vivo data showcasing the effectiveness of DC-9476 in cells obtained from RA patients who haven't responded adequately to methotrexate (MTX-IR). This presentation is expected to shed light on a treatment that could address a significant gap in current RA therapies.
The Challenge of Treating Rheumatoid Arthritis
RA is a pervasive condition, affecting approximately 1% of the global population. Alarmingly, around half of these patients qualify as MTX-IR, highlighting a substantial gap in effective treatment options. A further 20% of patients are classified as difficult-to-treat (D2T RA) due to their lack of response to both conventional and biological disease-modifying anti-rheumatic drugs (DMARDs). There exists an urgent need for innovative therapies that can deliver reliable outcomes for these individuals.
The Unique Mechanism of Action of DC-9476
DC-9476 is distinct in its action as it targets multiple inflammatory pathways simultaneously. Data suggests that it effectively decreases macrophage activation and Th17 differentiation, alongside reducing levels of IgG and pro-inflammatory cytokines such as TNF?, IL-6, IL-17A, and IL-17F. This multi-targeted approach may provide advantages over therapies that address only a single target, particularly in patients suffering from autoimmune diseases exacerbated by multiple immune pathways.
Preclinical Studies Highlight Efficacy and Safety
In extensive preclinical evaluations, DC-9476 demonstrated remarkable potential as a therapy for RA. In the CIA model, it led to a dose-dependent reduction in both arthritis scores and paw thickness while maintaining a safety profile devoid of hematological or other toxicities across a wide dose range. The treatment outperformed established therapies such as the anti-TNF? antibody etanercept, the JAK inhibitor tofacitinib, and the anti-IL6 antibody.
Impact on Key Disease Biomarkers
A particularly promising aspect of DC-9476 is its effect on peripheral blood mononuclear cells (PBMC) from patients who are MTX-IR. The treatment resulted in a significant reduction in the secretion and gene expression of IL-6 and CCL2—biomarkers that are crucial in assessing disease activity and progression.
Presentation Details and Future Directions
The upcoming presentation will detail the extensive findings associated with DC-9476.
Poster Title: DC-9476, a novel selective BRD4 (BD2) inhibitor targets key inflammatory arthritis pathways and is highly efficacious in the collagen induced arthritis mouse model of rheumatoid arthritis
Session: RA – Animal Models Poster
Date/Time: November 17, 2024, 10:30 AM – 12:30 PM ET
Presenter: Dr. Kulveer Mankia, Clinical Associate Professor and Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital
According to Kfir Schreiber, CEO & Co-Founder of DeepCure, "DC-9476 has consistently shown in vivo superiority over etanercept, and now we’ve observed in vivo superiority over tofacitinib and a reduction of clinical biomarkers in samples from MTX-IR patients. The data presented at ACR further support the progression of DC-9476 into clinical development as a novel treatment for RA."
About DeepCure
DeepCure is at the forefront of developing new therapeutic solutions aimed at transforming the treatment landscape for inflammation and autoimmune diseases. Established by researchers from MIT, the company leverages cutting-edge AI and AI-enabling technologies to accelerate the discovery of small molecules with the potential to change patient outcomes significantly. With a dedicated team of engineers, chemists, and biologists based in Boston, MA, DeepCure focuses on challenging problems that can significantly enhance patient health and well-being.
Frequently Asked Questions
What is DC-9476?
DC-9476 is a selective BRD4 (BD2) inhibitor that shows promising efficacy in treating rheumatoid arthritis, outperforming several existing therapies.
When will the findings from the DC-9476 studies be presented?
The studies will be presented at ACR Convergence 2024 on November 17, 2024, during the RA – Animal Models Poster session.
Who is presenting the data on DC-9476?
Dr. Kulveer Mankia will present the data, bringing his expertise as a Clinical Associate Professor and rheumatologist.
What significance do the findings hold for rheumatoid arthritis patients?
The findings indicate that DC-9476 may offer a new treatment option for patients who have not responded to traditional therapies, addressing a crucial unmet need.
How does DC-9476 compare to existing RA therapies?
DC-9476 has shown superior efficacy in preclinical models when compared to existing treatments like etanercept and tofacitinib, making it a promising candidate for further clinical development.
